Biogen shrinks research team, zeros in on external innovation
3 days ago · Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after receiving an “unsolicited” buyout offer. Biogen and Sage originally ...
Biogen Trims Research Workforce, Higher-Dose SMA Drug
2 days ago · Biogen will be laying off an undisclosed number of employees from its research unit, a company spokesperson confirmed to BioSpace on Thursday.. Also Thursday morning, the company announced positive news with the acceptance of a supplemental new drug application for higher-dose Spinraza, an Ionis-partnered drug for spinal muscular atrophy (SMA), by the FDA and the European Medicines Agency (EMA).
FDA and EMA Accept Applications for Higher Dose Regimen of …
3 days ago · About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. ... These statements speak only as of the date of this news release. We do not undertake any obligation to publicly update any ...
Sage seeks injunction after Biogen's unsolicited buyout offer
5 days ago · Biogen already owns about 6.2 million shares, or roughly 10%, of Sage. The decline in Sage’s stock price reflects the setbacks the biotech has suffered in recent years. Zurzuvae’s value was ...
FDA and EMA review Biogen's higher dose SMA drug - MSN
In other recent news, Biogen Inc. continues to make headlines with a series of significant developments. The biotech company's disciplined growth strategy has earned it an Outperform rating from ...
Sage Sues Partner Biogen After Unsolicited Takeover Offer
4 days ago · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law.. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted that it “is seeking preliminary injunctive relief to enforce a standstill agreement and a ...
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
News - Biogen
Jan 13, 2025 · Biogen Appoints Adam Feire as Head of Business Development and External Innovation
Biogen’s higher dose Spinraza under review by US and EU …
2 days ago · Spinraza pulled in $1.74bn in sales for Biogen in 2023, as per the company’s financials. Sales of the drug are set to decrease steadily year-on-year, generating $1.15bn in 2030, according to ...
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25
Jan 15, 2025 · Biogen also bought Human Immunology Biosciences last year for $1.15 billion upfront, at least momentarily silencing the constant drum beat of analysts and investors asking for a deal. But of course heading into J.P. Morgan that call had picked up again. Biogen did announce a potential deal, an unsolicited bid for partner Sage Therapeutics ...